Feature | November 04, 2013

Event-Free Patients May Not Need Long-Term DAPT After PCI

Results of the ARCTIC-INTERRUPTION Trial Presented at TCT 2013

cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic
November 4, 2013 — Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet therapy (DAPT) according to the results from the ARCTIC-INTERRUPTION trial, which was presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
The optimal length of time for DAPT after coronary stenting remains uncertain with an unknown safety-to-efficacy ratio of prolonged therapy. Currently, there are discrepancies between international guidelines and high variability in routine practice. The ARCTIC-INTERRUPTION study was a prospective, randomized trial that examined the benefit of the continuation of DAPT for up to two years. 
 
ARCTIC-INTERRUPTION randomly assigned 1,259 patients without major events within the first year after coronary stenting to either a strategy of interruption of DAPT (n = 624) or a strategy of continuation for an additional year (n = 635). The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke or urgent revascularization after one year. 
 
The primary endpoint occurred in 3.8 percent of patients in the continuation group as compared to 4.3 percent in the interruption group. The main secondary endpoint of stent thrombosis or any urgent revascularization occurred in 1.3 percent of patients in the continuation group and 1.6 percent of those in the interruption group. The rate of major bleeding events occurred in 1.1 percent of the patients in the continuation group compared to 0.2 percent in the interruption group. 
 
“The ARCTIC-INTERRUPTION study suggests no ischemic benefit of DAPT continuation beyond one year after stenting in patients that do not experience an adverse event within the first year,” said Gilles Montalescot, M.D., Ph.D., professor of cardiology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France, and lead investigator of the study. “Further, the study found significantly more major and minor bleeding events with DAPT continuation." 
 
For more information: www.crf.org

Related Content

biomimics, 3D stent
News | Peripheral Arterial Disease (PAD)| August 28, 2015
August 28, 2015 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania and second in th
iFR, FFR, Philips, Volcano
News | Cath Lab| August 28, 2015
August 28, 2015 — Philips Healthcare is showcasing its latest cardiology solutions at the European Society of Cardiol
News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
Stent graft, computational fluid dynamics, CFD, stent engineering

In this vector velocity model, brighter colors indicate blood flow acceleration as it passes through a bifurcation. Computation fluid dynamic modeling provides insight on blood flow through and near the walls of the stent graft. Image courtesy of Sanford Health

News | Cath Lab| August 27, 2015
August 27, 2015 — The use of computational fluid dynamics (CFD) modeling has been used for years to better engineer l
News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in

Mitral regurgitation viewed under color Doppler. Image courtesy of Toshiba.

Feature | Heart Valve Repair| August 26, 2015
August 25, 2015 — Medtronic announced it entered a definitive agreement to acquire Twelve Inc., a start–up medical de
NuCART, CompView Medical, mobile boom system, cath lab, hybrid OR
Technology | Cath Lab| August 21, 2015
August 21, 2015 — CompView Medical announced the release of the NuCART, a turn-key, all-in-one mobile boom system wit
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Corindus, Corpath, radiation dose monitoring, cath lab, vascular robotic system

The Corindus Corpath vascular robotic system.

Technology | Radiation Dose Management| August 19, 2015
Corindus Vascular Robotics Inc. and Unfors RaySafe Inc., a Fluke Biomedical Company, announced a distribution agreement...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
Overlay Init